Publicaciones (23) Publicaciones de ROBERT MONTAL ROURA

2024

  1. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis

    Critical Reviews in Oncology/Hematology, Vol. 201

2023

  1. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

    Molecular Cancer, Vol. 22, Núm. 1

  2. Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma

    Hepatoma Research, Vol. 9

  3. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

    Gut, Vol. 73, Núm. 3, pp. 496-508

  4. PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

    International journal of molecular sciences, Vol. 24, Núm. 13

2022

  1. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3443-3451

2021

  1. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

    Gastroenterology, Vol. 161, Núm. 3, pp. 879-898

  2. Microenvironmental reactive oxygen species in colorectal cancer: Involved processes and therapeutic opportunities

    Cancers, Vol. 13, Núm. 20

  3. The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy

    Journal of Laryngology and Otology, Vol. 135, Núm. 11, pp. 970-975

2020

  1. Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6350-6361

  2. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

    Journal of Hepatology, Vol. 73, Núm. 2, pp. 315-327

  3. Prognostic factors involved in the epithelial– mesenchymal transition process in colorectal cancer have a preponderant role in oxidative stress: A systematic review and meta-analysis

    Cancers, Vol. 12, Núm. 11, pp. 1-28

2019

  1. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

    British Journal of Cancer, Vol. 121, Núm. 4, pp. 340-343

  2. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

    Gut, Vol. 68, Núm. 6, pp. 1065-1075

  3. New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

    Clinical Liver Disease, Vol. 14, Núm. 2, pp. 56-61

  4. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

    Journal of Hepatology, Vol. 70, Núm. 6, pp. 1262-1277

2018

  1. Molecular therapies and precision medicine for hepatocellular carcinoma

    Nature Reviews Clinical Oncology, Vol. 15, Núm. 10, pp. 599-616

2017

  1. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

    Journal of Hepatology, Vol. 66, Núm. 5, pp. 952-961

  2. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1166-1172

  3. Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

    Journal of Hepatology